Everything on Pharmaceutical Risk

Novartis' failure to demonstrate cardiovascular benefits for its LPA drug has cast doubt on the entire class of next-generation cholesterol therapies. This has led to a sharp decline in the company's stock and affected peers.

Impact: The setback highlights the high risk in late-stage drug development and may slow down investment in similar lipid-lowering therapies, impacting the broader biotech sector.

— from Crypto Tax Shift, AI Disruption, and NFL Data Monetization · Alles auf Aktien – Die täglichen Finanzen-News· Sep 09, 2026